华蟾素联合酚妥拉明治疗慢性乙型肝炎48例疗效观察

Observation on Effect of Cinobufotalin and Phentolamine Treating 48 Cases of Chronic Hepatitis B

目的 观察华蟾素联合酚妥拉明治疗慢性乙型肝炎的临床疗效。方法 将血清病毒标志物阳性 (HBVM )伴肝功异常的慢性乙型肝炎患者 92例 ,随机分为治疗组和对照组。治疗组 48例 ,用华蟾素联合酚妥拉明 ,对照组 44例 ,只用华蟾素治疗 ,疗程均为 60天。结果 治疗组HBsAg阴转 2例 (4 .2 % ) ,HBeAg阴转 17例 (3 5 .4% ) ,HBV DNA阴转 2 1例 (4 3 .8% ) ,对照组HBsAg阴转 1例 (2 .3 % ) ,HBeAg阴转 15例 (3 4.1% ) ,HBV DNA阴转 19例 (4 3 .8% ) ,对肝功能的改善两组均有明显效果 ,但治疗组优于对照组 (P <0 .0 1)。结论 华蟾素抑制乙肝病毒复制 ,促进HBsAg、HBV DNA阴转 ,改善肝功能 。

Objective To observe the clinical effectiveness of the combination of cinobufotalin and phentolamine treating chronic hepatitis B patients.Method 92 cases of chronic hepatitis B with positive serum virus markes and abnormal liver function were divided into treatment group(n=48) and control group(n=44) randomly.48 patients in the treatment group were treated with the combination of cinobufotalin and phentolamine for sixty days.44 patients in the control group were treared with cinobufotalin only for sixty days.Results In the treatment group,the HBV DNA of 2 patients turned into negative(4.2%),the HBeAg of 17 patients turned into negative(35.4%),the HBV DNA of 21 patients turned into negative(43.8%).In the control group,the HBeAg of 1 patient turned into negative(2.3%),the HBsAg of 15 patients turned into negative(34.1%),the HBV DNA of 19 patients turned into negative(43.8%).In both groups,the liver function were improved,but those in the treatment group were significantly better than those in the control group( P <0.01).Couclusions: Cinobufotalin can inhibit the replication of hepatitis B vivus,make HBsAg and HBV DNA become negative and improve liver function.The combination of phentolamine and cinobufotalin may increase the effecftveness.